Consonance Capital Management is Fond of Healthcare Stocks

Consonance Capital Management is a New York based hedge fund established in 2005, managed by Mitchell Blutt MD. The firm usually invests in the lower middle market, in value stocks of small and mid-cap companies, focusing on the healthcare sector (payors, pharmaceutical, specialty distributors, and device manufacturers). CEO Mitchell Blutt uses his medical training and knowledge to identify attractive investment opportunities, companies with potential, within this segment. Before founding Consonance Capital, Mr. Blutt worked as Executive Partner at J.P. Morgan Partners.

A few days ago, the fund filed a Form 13F at the SEC, disclosing its long equity positions as of March 31 2014. It declared holding 37 different positions, all of them in the healthcare sector. Newcommers in the portfolio were represented by 10 of these holdings, and another 14 saw the fund increase its stakes over the quarter. Let’s take a closer look at the top holdings in this portfolio, valued at more than $672 million, and some of the moves that took place over Q1.

United Therapeutics Corporation (NASDAQ:UTHR)

Mr. Blutt’s top position remained the same: United Therapeutics Corporation (NASDAQ:UTHR). In fact, this $4.8 billion market cap biotechnology company saw the fund’s stakes increase by 15% over Q1. Consonance now owns 669,690 shares of the company, worth more than $67 million, which accounts for more than 9% of the total value of its equity portfolio. This makes it the second largest hedge fund shareholder, only trailing William Leland Edwards’ Palo Alto Investors, which owns 1.1 million shares.

The second place was occupied by a new stock in Consonance’s equity portfolio: Myriad Genetics, Inc. (NASDAQ:MYGN), a $2.5 billion market cap company engaged in the discovery and commercialization of transformative tests which assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Over the first quarter, Mr. Blutt’s fund acquired 1.74 million shares, valued at approximately $58 million. However, this stake becomes quite small when compared to Royce & Associates’. The fund managed by Chuck Royce owns about $314 million in the company’s stock.

Furiex Pharmaceuticals Inc (NASDAQ:FURX) is the only one of Consonance’s top five positions for Q1 that saw a decrease in its stakes. However, the bet placed on this $1.1 billion market cap drug development collaborate company is still quite big: 616,495 shares, worth about $64 million. This position makes Consonace the largest hedge fund shareholder at the company. Second in rank, with about half the shares (376,365), is Israel Englander’s Millennium Management.

Back to bullish moves, we have Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a $716 million market cap research and development focused biotechnology company. In its last 13F, Consonance disclosed ownership of 1.25 million shares (up 47% in relation to Q4), valued at roughly $48 million. Once again, Mr. Blutt’s fund is the company’s largest hedge fund stockholder

Finally, there’s BioScrip Inc (NASDAQ:BIOS), a $505 million market cap provider of home infusion and other home healthcare services. Over the quarter, the fund acquired 1.1 million shares, and now owns more than 5 million of them. This position, worth about $37 million, makes of the fund, yet again, the largest hedge fund investor, trailed, for a second time, by Englander’s Millennium Management, with 2.1 million shares.

Disclosure: Javier Hasse holds no position in any stocks mentioned.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!